Replies to post #378717 on Amarin Corp Plc (AMRN)

[Number sleven]

Raf, Thanks for the numbers.
Sleven,

[Gusman]

Thanks Rafunrafun, always appreciate the effort you put in for us all.

[dogn]

Raf, Thanks for sharing these week after week. Appreciate it. Down but less than overall market, & half the % decline of competition. A small win.
-dogn

[rafunrafun]

Scripts for week ending May 27, 2022

Drug Industry TRx: +0.8% w/w; +6.6% y/y

Vascepa
TRx 63,370; -3.6% (-2,366) w/w; -25.0% y/y
NRx 29,093; -4.0% (-1,196) w/w; -22.3% y/y
Ref 34,277; -3.3% (-1,169) w/w; -27.1% y/y

Lovaza (Generic & Brand)
TRx 62,388; +0.7% (+427) w/w; -1.3% y/y
NRx 31,598; +0.9% (+297) w/w; +2.4% y/y
Ref 30,789; +0.4% (+130) w/w; -4.8% y/y

Generic Vascepa
TRx 36,969; +0.0% (+16) w/w; As % of total V: 36.8%
NRx 20,181; -2.0% (-411) w/w; As % of total V: 41.0%
Ref 16,787; +2.6% (+427) w/w; As % of total V: 32.9%

Generic Vascepa by Manufacturer
Hikma - TRx 10,312; (+590) w/w; Generic share 27.9%; Total V share 10.3%
Reddy - TRx 18,716; (+137) w/w; Generic share 50.6%; Total V share 18.7%
Apotex - TRx 7,941; (-711) w/w; Generic share 21.5%; Total V share 7.9%

Vascepa + Generic Vascepa
TRx 100,339; -2.3% (-2,350) w/w; +5.0% y/y
NRx 49,275; -3.2% (-1,608) w/w; +12.8% y/y
Ref 51,064; -1.4% (-742) w/w; -1.6% y/y